Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study
Hideaki Jinnouchi, Masayoshi Koyama, Atsushi Amano, Yoshinori Takahashi, Akira Yoshida, Kunio Hieshima, Seigo Sugiyama, Noboru Kurinami, Tomio Jinnouchi, Reinhard Becker, Hideaki Jinnouchi, Masayoshi Koyama, Atsushi Amano, Yoshinori Takahashi, Akira Yoshida, Kunio Hieshima, Seigo Sugiyama, Noboru Kurinami, Tomio Jinnouchi, Reinhard Becker
Abstract
Introduction: New insulin glargine 300 U mL(-1) (Gla-300) is a basal insulin that shows more stable and prolonged pharmacokinetic and pharmacodynamic profiles than insulin glargine 100 U mL(-1) (Gla-100). This study used continuous glucose monitoring (CGM) to compare 24-h glucose profiles in a Japanese population using Gla-300 versus Gla-100.
Methods: This was an exploratory 8.4-week, single-center, 2-sequence, 2-period, open-label crossover study. Japanese adults with type 1 diabetes mellitus (T1DM) treated with basal-bolus insulin, with glycated hemoglobin (HbA1c) 6.5-10.0% and median fasting self-monitored plasma glucose concentration ≤13 mmol L(-1), were randomized to Gla-300 followed by Gla-100 (subgroup 1) or vice versa (subgroup 2), with no washout period. CGM was performed on the last 3 days of the screening period and each treatment period. Primary endpoint was comparison of 24-h glucose variability (area under the curve [AUC]mean_24 h) on the second day of each CGM measurement with Gla-300 versus Gla-100. Baseline and end of treatment period values for HbA1c, fasting plasma glucose (FPG) and daily basal/mealtime insulin doses were recorded. Hypoglycemia and adverse events (AEs) were recorded.
Results: Twenty participants were randomized (10 to subgroup 1 and 10 to subgroup 2). Participants showed comparable glucose variability over 24 h (AUCmean_24 h during treatment with Gla-300 or Gla-100 (treatment ratio 0.96; 90% confidence interval 0.79, 1.16). HbA1c and FPG were generally stable across both treatment periods. There was a trend towards fewer participants experiencing ≥1 hypoglycemia event at any time (24 h) and at night (00:00-05:59 h) with Gla-300 versus Gla-100. Treatment-emergent AEs, reported by 9/20 (45%) and 4/20 (20%) participants during Gla-300 and Gla-100 treatment, respectively, were unrelated to study medication.
Conclusions: In this cohort of Japanese people with T1DM, no between-treatment difference was observed in glucose variability with Gla-300 versus Gla-100, as measured by CGM. There was a trend for less hypoglycemia with Gla-300, particularly at night, versus Gla-100. Both treatments were well tolerated.
Funding: Sanofi, Tokyo, Japan.
Clinical trial registration: NCT01676233, ClinicalTrials.gov.
Figures
References
- Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units mL−1. Diabetes Care. 2015;38:637–643.
- Becker RH, Nowotny I, Teichert L, Bergmann K, Kapitza C. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17:261–267. doi: 10.1111/dom.12416.
- Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254–260. doi: 10.1111/dom.12415.
- Riddle MC, Bolli GB, Zieman M, et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal and mealtime insulin: glucose and hypoglycemia in a 6-month randomized controlled trial (EDITION I) Diabetes Care. 2014;37:2755–2762. doi: 10.2337/dc14-0991.
- Yki-Järvinen H, Bergenstal RM, Zieman M, et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care. 2014;37:3235–3243. doi: 10.2337/dc14-0990.
- Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) Diabetes Obes Metab. 2015;17:386–394. doi: 10.1111/dom.12438.
- Home PD, Bergenstal R, Riddle MC, et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015. doi:10.2337/dc15-0249 (In press).
- Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP 1) Diabetologia. 2014;57:S400.
- Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T. Glycemic control and hypoglycaemia in Japanese people with type 2 diabetes mellitus receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP 2) Diabetologia. 2014;57:S401.
- Bergenstal R, Bailey T, Robard D, et al. Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM). Diabetes Technol Ther. 2015;17:A16-17 (abstract 39).
- ICH. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice E6 (R1). 1996. . Accessed 21 May 2015.
- World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. 2013. ]. Accessed 21 May 2015.
- Workgroup on Hypoglycemia ADA Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245–1249. doi: 10.2337/diacare.28.5.1245.
Source: PubMed